A Multicentre Randomized Placebo-Controlled Double-Blind Clinical Trial for Evaluation of Safety and Efficacy of a Specific Immunotherapy With an Aluminium Hydroxide-Adsorbed Allergoid Preparation of House Dust Mite (Dermatophagoides Pteronyssinus) in Patients With Rhinitis/Rhinoconjunctivitis and/or Allergic Asthma Bronchiale.

Trial Profile

A Multicentre Randomized Placebo-Controlled Double-Blind Clinical Trial for Evaluation of Safety and Efficacy of a Specific Immunotherapy With an Aluminium Hydroxide-Adsorbed Allergoid Preparation of House Dust Mite (Dermatophagoides Pteronyssinus) in Patients With Rhinitis/Rhinoconjunctivitis and/or Allergic Asthma Bronchiale.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Feb 2013

At a glance

  • Drugs House dust mite allergy immunotherapy (Primary)
  • Indications Allergic asthma; Rhinitis; Rhinoconjunctivitis
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors Allergopharma
  • Most Recent Events

    • 05 Nov 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top